Dulaglutide vs Exenatide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Dulaglutide
Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction. Engineered as a GLP-1 analogue fused to a modified IgG4-Fc domain, which provides a ~5-day half-life and enables once-weekly subcutaneous dosing via a simple auto-injector pen with no reconstitution required.
Full profileExenatide
First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits.
Full profile| Dulaglutide | Exenatide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Trulicity, LY2189265 | Byetta, Bydureon, AC2993, exendin-4 |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 0.75mg–4.5mg mg, once weekly subcutaneous | 5mcg–2mg (weekly ER) mcg, Twice daily (immediate-release) or once weekly (extended-release) |
| Administration | Subcutaneous injection (auto-injector pen) | Subcutaneous injection |
| Key side effects | Nausea (most common), Diarrhea, Vomiting, Abdominal pain | Nausea (most common, especially initial weeks), Vomiting, Diarrhea, Injection site nodules (extended-release formulation) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Dulaglutide — Subcutaneous injection (auto-injector pen); Exenatide — Subcutaneous injection.
- Dosing units differ: Dulaglutide is dosed in mg, Exenatide in mcg — they operate at different scales.
- Frequency: Dulaglutide is typically once weekly subcutaneous; Exenatide is Twice daily (immediate-release) or once weekly (extended-release).
How each works
Dulaglutide
Dulaglutide's large molecular structure (fusion with IgG4-Fc) prevents renal filtration and extends half-life via FcRn recycling, enabling once-weekly dosing. The REWIND cardiovascular outcomes trial demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with or at risk for cardiovascular disease, establishing dulaglutide as a cardioprotective agent beyond glucose control.
Exenatide
Exenatide was identified from Gila monster (Heloderma suspectum) venom as exendin-4, a peptide with ~53% homology to human GLP-1 but with DPP-4 resistance enabling longer activity. Clinical trials demonstrated HbA1c reductions of 0.8–1.0%, weight loss of 2–4kg, and cardiovascular safety (EXSCEL trial showed non-inferiority). The extended-release microsphere formulation achieved comparable efficacy with once-weekly dosing.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.